Summary
Aqueous influenza vaccines seldom induce longpersistent protection against epidemic risk, and often fail to immunize up to one-third of the recipients, especially when there has been no previous immunological experience of the serotype of virus contained in the vaccine. Attempts to improve the situation by increasing the size or number of doses are limited by expense, toxicity and the time available in face of an oncoming epidemic. The future use of isolated viral antigens as vaccines may be limited by similar disadvantages.
Immunological adjuvants may make a valuable contribution in decreasing the minimum effective dose of antigen, thereby reducing the toxicity and expense of the vaccine, and increasing its availability. Adjuvant vaccines used in the past have been shown to induce higher mean titres of circulating virus-neutralizing or HI antibody in a higher proportion of the population than have aqueous vaccines, and the duration of immunity has been prolonged. The choice of adjuvants and the avoidance of untoward side-effects are discussed in this review. THE (Meichen, Rogan & Howell, 1962) health authorities and large industrial organizations are reluctant ever to initiate mass vaccination campaigns against influenza, since they could be faced with the problem of annual revaccination to maintain the status quo.
The immune response to aqueous vaccines is often worse&than after natural infection, not only in terms of strictly homologous serum HI antibody, but also in the spectrum of serological activity against other influenza A viruses of the same sub-type but with minor degrees of antigenic drift. Brown, Gajdusek & Morris (1969) found that isolated communities in Micronesia, with no pre-existing exposure to A2 viruses, developed lower titres of homologous antibody after vaccination with 300 CCA of A2/Tai/1/64 than after natural infection with an antigenicallyidentical strain ( Fig. 2 ) and showed significantly less induction of cross-reacting HI antibody against the earlier A2 strains of 1957-62. Similarly, Weibel et al. (1967) found that aqueous vaccines of a particular A2 strain confer little serological activity against sequentially later antigenic variants.
These immunological shortcomings of aqueous preparations may well become even more pronounced when separated purified HA and neuraminidase (N) antigens come into more general use in place of the whole virus particle, with the removal of the inbuilt adjuvant effect of a large carrier rich in lipid. The low efficiency of recovery and the cost and time involved in antigenic separation would make it difficult to compensate for any such loss of immunogenicity by increasing the size or number of doses per patient, especially in a crash programme of vaccination against a new virus serotype.
The need for a reliable artificial immunological adjuvant of influenza vaccines is therefore obvious, and anything which could make a poor antigen good, or a good antigen better is worth exploring. In the past 20 years literally everything from tapioca to tubercle bacilli and from shark oil to sesame seeds have been investigated, and from the more recent studies of White (1967) and Gall (1967) Thirdly, general stimulation of the reticuloendothelial system may be important; adjuvants such as Corynebacterium parvum, bacterial endotoxins, and oligonucleotides need not necessarily be given at the same site or even at the same time as the antigen to exert an adjuvant effect.
Simple compounds such as aluminium salts which are effective adjuvants of bacterial toxoids seem to be of little value with whole virus vaccines (Himmelweit, 1960) , presumably because the 'carrier' function of the alum molecules is obviously impossible with such gross particles. However, this type of adjuvant will deserve re-investigation when isolated smallmolecular antigens of influenza such as crystalline HA (Brand & Skehel, 1972) become available as vaccines.
The only influenzal adjuvants which have been investigated clinically are all variations of the original depot technique of Freund & McDermott (1942) omitting tubercle bacilli which are obviously not feasible in human vaccines, refining the oil and emulsifier, and defining the optimal viscosity of the oil-vaccine emulsion (Berlin, 1960) . The adjuvant vaccine used most commonly for the last 25 years in clinical trials in the USA (Davenport, 1961) and Britain (Hobson et al., 1964) and more recently in commercial production in Britain has been a thick stable water-in-mineral-oil emulsion (Fig. 3a) with antigen slowly released from the discontinuous phase. Many clinicians and licensing authorities have been worried about the irritant effects and long persistence of these non-metabolizable mineral oils in the tissues, and about the remote possibility of their carcinogenicity. Hence Hilleman and his colleagues (1972) have over the past 8 years developed an alternative thick emulsion vaccine, Adjuvant 65, in which the base is readily-metabolized peanut oil. Herbert (1967) developed an ingenious modification (Fig. 3b) , whereby a thin compound or reversed-phase emulsion is made by redispersing the original thick adjuvant to give an antigen-in-water-in-oil-in-water emulsion which is far easier to dispense and inject, less likely to give inflammation or nodulation at the site of injection because it disperses freely throughout the whole RE system, and evokes for this reason an even greater immune response than thick emulsions.
It has long been known that water-in-mineral-oil (1953) showed (Fig. 4) , 1953) . Moreover, antigenic extinction titrations in volunteers (Fig. 5) show that considerably less virus is required to produce a given rise in antibody when oily adjuvant is used. In subsequent adjuvant vaccine trials with a variety of influenza virus strains serological advantages similar to those described above have been obtained with antigen doses 5-10 times lower than those in conventional aqueous vaccines (Davenport, 1961; Hobson et al., 1964; Herbert, Selwyn & Philp, 1965) .
Thus, one of the greatest potential advantages of immunological adjuvants is to allow a larger number of people to be immunized early after a new epidemic virus has emerged, with vaccine doses small enough to obviate many of the toxic side-effects of aqueous influenza vaccines. Although postvaccine HI titres are usually significantly lower in people with no detectable antibody before adjuvant vaccine than in those with prevaccine experience of the antigen (Hobson, 1967) , it is clear that even as a primary immune stimulus a low-dose adjuvant vaccine is better than higher doses in aqueous form. Thus, as shown in Fig. 6 , when A/Swine vaccine was given to young children who could not have had prior experience of this antigen (Hennessy & Davenport, 1961) , an initial dose of 60 CCA of adjuvant vaccine gave higher initial HI titres than 200 CCA in aqueous form, and established an effective immunological memory. A second vaccine dose 7 months later gave a good booster response, and although antibody titres subsequently declined the mean level 1 year later was sixteen-fold higher than after aqueous vaccine.
By further manipulation of the size and number of doses, and of the constitution of the adjuvant emulsion it is possible to maintain high HI titres for at least 7 years after vaccination, and the incorporation of polynucleotides (poly IC) in adjuvant 65 xaccine gives a further 'synergistic hyper-potentiation' of the immune response (Hilleman et al., 1972) . However, it seems doubtful if there is any clearcut advantage in the short term in raising the level of serum HI antibody to a level so many times higher than that needed to protect against homologous infection (Hobson et al., 1972) With the undoubted advantages of adjuvant influenza vaccines it is surprising at first sight that they are not already being used on a national commercial scale. The first reason is that it has always been very easy to make a water-in-oil vaccine which does not work. Emulsified vaccines are elegant pharmaceuceutical preparations which require a high degree of skill and care in manufacture, storage and injection if serious untoward effects are to be avoided. The frequency of toxic reactions and nodulation is low, but still unacceptably high for mass vaccination campaigns. Part of the trouble lies with the oils and emulsifiers being insufficiently characterized, but much of the blame falls on the antigen itself-in the past crude whole virus preparations have been used, and the adjuvant will indiscriminately augment Further theoretical disadvantages of adjuvant vaccines still remain to be solved-in animals, it is well known that adjuvants can modify the expression of antigenic determinants, can change the ratio of the various antibody classes and can change the balance between antibody-mediated and cell-mediated immunity (White, 1967) . If these events were to happen in man, the possibility of Arthus or delayed hypersensitivity reactions to viral antigens on subsequent vaccination or infection would constitute an unjustified risk, perhaps greater than that of the uncontrolled disease. It must be remembered that epidemic influenza is mainly a socio-economic risk, at the general population level, only once in a decade. To the average individual, influenza is only one of many trivial self-limiting respiratory infections with none of the emotive overtones of poliomyelitis or smallpox. Thus, the safety and purity of influenza vaccines is of paramount importance if they are ever to be accepted by patients on the large scale which alone could control future pandemics.
